Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-13237.27%
operating margin TTM
-14095.8%
revenue TTM
735.36 Thousand
revenue per share TTM
0.01$
valuation ratios | |
|---|---|
| pe ratio | -4.20 |
| peg ratio | -0.48 |
| price to book ratio | 4.35 |
| price to sales ratio | 560.14 |
| enterprise value multiple | -4.25 |
| price fair value | 4.35 |
profitability ratios | |
|---|---|
| gross profit margin | 74.8% |
| operating profit margin | -14095.8% |
| pretax profit margin | -13237.27% |
| net profit margin | -13237.27% |
| return on assets | -79.07% |
| return on equity | -77.23% |
| return on capital employed | -109.44% |
liquidity ratios | |
|---|---|
| current ratio | 4.20 |
| quick ratio | 4.20 |
| cash ratio | 0.69 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 243.33 |
| days of payables outstanding | 9,280.89 |
| cash conversion cycle | -9,037.55 |
| receivables turnover | 1.50 |
| payables turnover | 0.04 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.02 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -41.80 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.63 |
| cash per share | 0.91 |
| operating cash flow per share | -0.63 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -41.80 |
| short term coverage ratios | -58.16 |
| capital expenditure coverage ratio | -959.61 |
Frequently Asked Questions
When was the last time Cardiff Oncology, Inc. (NASDAQ:CRDF) reported earnings?
Cardiff Oncology, Inc. (CRDF) published its most recent earnings results on 06-11-2025.
What is Cardiff Oncology, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cardiff Oncology, Inc. (NASDAQ:CRDF)'s trailing twelve months ROE is -77.23%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cardiff Oncology, Inc. (CRDF) currently has a ROA of -79.07%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CRDF's net profit margin stand at?
CRDF reported a profit margin of -13237.27% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CRDF's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.20 in the most recent quarter. The quick ratio stood at 4.20, with a Debt/Eq ratio of 0.02.